 |
We are advised by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. that journalists and other readers should disregard the news release, Kelun-Biotech's Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer, issued 12-Jun-2025 over PR Newswire.
source: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
【說說心理話】照顧者壓力大 情緒出現問題應找心理醫生！嘉賓：「雖然很貴，但是值得的，他救了我一命！」► 即睇
